K药险胜成功卫冕,司美格鲁肽提前锁定2025年药王?

医药地理
06 Feb

双双逼近300亿美元2月4日,默沙东公布2024年财报,总营收达641.68亿美元,同比增长7%。默沙东制药业务收入574.00亿美元,同比增长7%。2023年的药王Keytruda(帕博利珠单抗)营收高达294.82亿美元,同比增长18%,其销售额约占默沙东全年总营收的46%,成功卫冕2024年的全球药王。图:默沙东财报2月5日,诺和诺德公布了2024年度财务报告。2024年,诺和诺德全球销售额...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10